RBC Capital Reiterates Sector Perform on Neurocrine Biosciences, Maintains $108 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has reiterated a 'Sector Perform' rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $108.
June 30, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has reiterated a 'Sector Perform' rating on Neurocrine Biosciences and maintained a price target of $108.
The reiteration of the 'Sector Perform' rating and maintenance of the price target by RBC Capital indicates that the analyst sees no significant changes in the company's performance. This could mean that the stock price will likely remain stable in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100